Charity registration number.. 1164238 Action Kidney Cancer Annu81 Report and Financial Stsiements for the Year Ended 31 October 2023
Action Kidney Cancer Contents (continued) Reference and Adminislralive Details Trustees. Report 2107 Statement of Trustees, Respon8ibililies Independent Ex8minels Report Statement of Financial Activities 10 B8lance Sheet 11 Notes to the Financial Statements 121019
Action Kidney Cancer Reference and Administrative Details Chairman A Thomas Trust0•$ A Thomas J Larkin JPYM A Fi8lding S Turajlic 1164238 Charity Regl$tf•tlon Number Principal Offlce 11th Floor 3 Piccadilly Manchester M1 3BN Indèp•ndont Examlnor Slockdale Accountants Ltd st Ingunger Offices Lanivel Bodmin Coinwall PL30 5HS Page 1
ACTION KIDNEY CANCER IAction Kidney Cancer isthe working name of'KidneyCancer Support Network'l Trustees Report forthe year ended 31st October2023 The Trustees present their report together with the financial Statement for the year ended 31 st October 2023. In preparing this report, the Trustees have adopted the piovi8ions of the Statement of Recommended Practice ISORPI"accounting and reporting by charities. issued in March 2005. Registered charity number: 1164238 in England Wales, SC051330 In Scotland Status: Charitable Incorporated Organisation {CIOI Incorporated 3 November2015 England Wales Status: Charitable Incorporated organisation (CIO) incorporaled 7 October2021 Scotland Princlpal and reglstered address: ACTION KIDNEY CANCER Kidney Cancer Support Network. 11 th Floor. 3 Piccadilly Place Manchester M1 3BN Trustees MrAndyThomas- Chair Professor James Larkin Mr jonathan Pym Professor Samra Turajlic Ms. Alison Fielding StruGturtygO¥ernanagernOnL ACTION KIDNEY CANCER began its work as a voluntary support organisation in 2006. ItW8S registered as a formal charitable incorporated organisation ICIOI on the 3 November 2015 and the charity is managed according to its governing documents dated 3 November 2015. The charity underwent a complete rebranding during in 2021 and is now known by its working name ACTION KIDNEYCANCER. Where there is a raquiiement fol new Trustetss, they will be identified and appointed by the current Trustees. The ACTION KIDNEY CANCER management team is responsible forthe induction ofany newTrustees, and this will involve a briefing about Trustee responsibilities, the governing document. and the adopted operating policies and procedures of the charity. All Trustees provide their services to the charity on a voluntary unpaid basis. The Trustees delegate day-to-day responsibility for the running of the charity to the management team who are accouniable to ttte Trustees and report to the Trustees throughout the year as required and at regular Trustee meetings.
The Trustees have a duty to identify and review all risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against Iraud and error. The Trustees regularly review the risks that the charity may face. and the Trustees will continue to monitor the risks associated with its activities and continue to be vigilant as to other risks that might be associated with a charity providing support services to people affected by kidney cancer. The Trustees have agreed and adopt8d a series of operating policies to ensure the charity runs smoothly and complies with all charity commission requirements and legal responsibiliti89. The operating policies are reviewed every two years and are available by written reques1 to the ACTION KIDNEY CANCER management team. Some policies are available via theACTION KIDNEY CANCER website. The Trustees declare as part of this annual return, that there are no serious incidents 01 other matters theTrustees should have reported tothe Charity Commission. Ch•rity objectives and activities To promote and protect th8 physical and mental health of patients with kidney cancer in the United Kingdom by: 1. The provision of information, support. education and practical advice to kidney cancer patients, their families, and their c8rers 2. To advance the education and awareness of all Inatters relating to kidney cancer with the general public 3. Promoti r¢g and supporting research projects into the causes, diagnosis, prevention, treatment, and cuie of kidney cancer and disseminating the results of such research. The Truste8s meet a minimum ot once a year, to discuss, agree and record charitable activities. strategy, funding piiorities. and operating policies, including risk management. Project meetings are held throughout the year as required andlor as requested by the Trustees or management team. Public beneflt The Trustees confirm that they have referred to the guidance provided by the charity commission's general guidance and advice on public benefit. In planning all activities including financial policies. the trustees confirm they have complied with the duty in section 17151 ol the 2011 Charities Act and the Trustees ar8 satisfied that all charitable activities during the year are for the benefit of the public. Achievement5 and performance ACTION KIDNEY CANCER is a patient and carey led kidney cancer charity with a ur)ique perspective and understanding of the needs of kidney cancer patients, carers. and theiT f8milies. ACTION KIDNEY CANCER provides information. support, and advocacyto anyone affected by kidney cancer and seeks to educate and inform the public in all aspects of kidney cancer. The year ending 31 October 2023 was a very busy and productive time for the charity. The aftermath of the COVID 19 pandemic is still having a significant impact on the ability of ihe NHS to meet car)cer waiting time standards 2nd this is having a sevefe impact on our patient community. Our m8nagem8Wlt t8am continue to work hard together. reaching out and supporting kidney c8nc8r patients and carers. The charity provides information about treatment optiofis, updates. and advice for patients about NHS waiting lists and delays, and how to access treatment options and care Services. The support cases can be complex, they are time-consuming and require a peTsonalised approach, but we know that Tecently diagnosed patients are particularly vulnerable and trying to
negoti8te their way around the complexities of the NHS system. adds signrficantly to their worries and fears. We are told ih3t the pandemic is still affecting the ability of the NHS to meet the demand for its services. Patients and their families bear the brunt of the delays and patients report long wait times for diagnosis and lengthy waits for surgery. There are delays for routine scans and the wait times for test results have lengthened up to and sometimes beyond, 6 weeks. Because of this, kidney cancer patients and their families turn to the charity for support and practical advice about how to navigate the complexities of the NHS system in order to get timely appointments, scan results and 2nd opinions. We are reliant on and thankful for the work of the ACTION KIDNEY CANCER managem8nttearn who have worked long hoLJrs throughout the year to support each othei in addition to providing bespoke support and advice to individual pat18nts and family members within our or71ine community forum. via our freephone helpline and via peer-to-peer email service and zoomlvideo links. In addition, we provide regular daily kidney cancer news, research. updates via our website and social media channels and we continue to provide practical information about the COVID 19 vaccination programm8 on our websit8 for the public and patients. Corè activltias. "Website. Our new website is updated daily with kidney cancer news, research, and campaigning updates. We continue to add and review content on a planned basis including a formal review of all patient information, clinical information, and policy documents. We are prep8ring to apply for the Health Information Policy for PIF Tick accreditation to increase the credibility of our patient resources. * Projects 2022123 In addition to our normal activities, we aim to produce several patient focused projects each year. The Renal Oncology Nurse Network is one such project.. following a talk and presentation at a nursing conference by management team member Karen McNee, we were approached to explore the feasibility of creating a renal cancer oncology nurse network with the aim of sharing best practices. providing u p-to-date news and research, and to work in partnership with the nurses to create a depository of renal cancer information and resources. The aim is to provide admin support for kidney cancer oncology nurses in their work with kidney cancer patients. We now have over 50 kidney cancer nurses in our Renal Oncology Nurse Network IRONN'SI, and many have received our literature for their clinics. We held a successtul inaugural online meeting on the18th October 2023 and have plans for a rolling programme of events over the coming ye8rs. We continued to add to our library of video interviews with expert clinicians and healthcare professionals designed to answer qLJestioTrs raised from within the community. The expert videos involve the charity management team interviewing clinicians and nurses with experience and knowledge of treatments and caiing for patients with kidney cancer. We were approached by Glasgow University to assist with writing 2 modules150% of the course) for the RCC4Nurses online training course. This course has been well Teceived and our medical writer Sharon D8Vgson Kèll is mentioned a# a collaborative author of this work. As part ofour international work, ACTION KIDNEYCANCER project managed and authored a comprehensive Decision Aid for patients considering participating in a clinical t1181. The booklet. called "My Treatment, My Choice- A decision aid to help people decide whether to take part in a clinical trial for kidney cancer" was published by IKCC Iwww.ikcc.orgi in April 2023 and Is freely
available to patients and HCPS around the world for anyone wanting to understand more about patient participation in kidney cancer clinicaltrials. Patient Involvement. We have been very proactive with our canceradvocacyorganisation partners, such as Cancer 52, Cancer Research UK, Macmillan Cancer Relief, Coalition for Reducing Bureaucracy in Clinical Trials, Independent Cancer Patient Voice IICPVI, and the ABPI Patient Organisation Forum. Advocacy on behalf of the kidney cancer community is a vital part of our work and ACTION KIDNEY CANCER is recognised nationally and internationally as a genuine patient-led charity pioviding a strong patient focussed voice. We continue to campaign publicly for meaningful patient involvement in all aspects of patient treatment and care, research, and survivorship. Clinical trialg. We continue to work with the scientific community and research establishments across the country to help impiuve geographical spiead. recruitment, and retention of kidney cancer patienls into clinical trials around the UK. We are frequently involved in clinical trial design and data management committees. we are called on to review andlor help write clinic81 trial Patient Information Sheets and clinical trial protocols. and review patient videos for clinical trials. As patient experts and representatives, we work in partnership with leading renal cancer clinicians, nLJrses, and members of the scientific community towards better care and treatment options and ultimately a cure for kidney cancer. We have continued to invest time and f unds in our unique kidney cancer clinical trials database on our website. The clinical trials database is a fullyfunctional searchable database written in patient- friendly language and complemented with a full glossary and a range of patiernt educational resources about clinical trials, both written and video format. We provide support and work with individual kidney cancer patients to h81p find suitable clinical trials which patients can then print off and discuss with their hospital team. Over the year, we were able to play a leading role in several campaigns and took the opportunity to provide a strong patient voice into several r¢ationally important pieces of work.. including RAMPART, REFINE, TRACERX, OPTIC and EqUATOR clinical trial groups. We belong to the Coalition for Reducing Bureaucracy in Clinical Trials where we have a role as lead for the'informed consent" working group. "Patient support. We provide the only'peer to peer" managed kidneycancer helpline in the UK. We provide a f riendly yet knowledgeable point of contact for patients and caTers to discus5 their concerns in an Dpen, impartial, and non-judgemental way. Our aim is to provide patients with an individual and personal service, providing quality evidence-based information and personal advocacy. Our private'peer to peer" online discussion forum has an 8Ctive membership of over 1400 kidney cancer patients, carers. and family members. Our support forum is available 2417 and is a unique support service Tnanaged and moderated by expert Patients. caregivers. and advocates. This is a busy yet welcoming online forum that offers evidence-based information. shared patient experiences and general patient and carer support. Our discussion forum regularly records over 7000 comments & inteiactions every month covering all aspects of living with kidney cancer such as sharing emotional and practical issues. including side effecls management. diet and well-being, family relationships. financial and work issues, survivorship, and bereavement and loss. *Campaigning. ACTION KIDNEY CANCER participated in the very successful International World Kidney Cancer Day in 2023. We led the UK campaign around a theme of'we need to talk about living with kidney cancer"providing expert patient vide05 and iaking part in the global symposium.
The charity was part of the policy team that led the Big Cancer52 Conversation. Action Kidney Cancer took the lead role for the'access to clinical trials" working group. Cornmunication. We continue to produce our valLt2ble professionallywritten quarterly ACTION KIDNEY CANCER newsletter updating our communityof patient. carers. and healthcare professionals with the latest kidney cancer research and reviews, interviews. and patient activities. We have written & distributed patient-fiiendly highlights from the main oncology conferences in Europe IESMO and the EAUI and North America IASCO and ASCO GUI and the IKCC Global Kidney Cancer Summit report. Keeping the patiènt community up to date with current research is an important area ofourwork. * Partnership working. We h8ve continued to provide an expert kidney cancer patient perspective at v2riotJs online meetings. webinars and virtual and face-to-face conferences organised by the National Health Service INHSI, Internation81 Kidney Cancer Coalition IIKCCI, pharmaceutical companies, National Institute for Health and Caie Excellence INICEI and the Scott15h Medicines Consortium ISMCI and the National Kidney CancerAudit. Action Kidney Cancer are members of the following organisationg.. Welsh Cancer Alliance, Scottish Cancer Coalition and Scottish Cross Party Gioup for cancer, Northern Ireland Cancer Coalition. We attend face-to-face and online meetings to ensure the kidney cancer patient perspectivo is heard. We collaborate with Cancer52, One Cancer Voice and All.Can on policy issues such as tackling inequalities, improving the cancer journey, reducing ingfficiencies in the healthcare system. the Major Conditions Strategyi and early diagnosis and prevention of cancer together with raising awareness ofAMR and the anti-smoking lobby. We work in partnership with the ABPI and took part in their conference on real world data. We attend regular meetings as a member of the ABPI patient involvement committee to ensure the patient voice is always heard in discussions with our pharmaceutical industry partners. Fundraising. Duringthe year. managementteam member Karen McNee oversaw several successful fundraising events including a parachute jump in Wales. a musical evening, and our very successful yearly event organised by management team member Steve Pointon and his family* the Northern Soul two-day dance event. We continue to promote the virtual Lands, End to John O'Groats project. the Mad Hatters Tea Party and our"Cift a Heart'campaign continuesto be successful. Oui c8sh ollections remain strong despite a diff icult economic climate. We also work in partnership with Project Flutter providing Butterfly Bags and comfort cushions to kidney cancer patients around the country. NICE and SMC Health TechnologyAppraisals and Consultations We have continued ourclear mission to provide evidence based, w811 researched, patient submissions to health technology appraisals IHTAI related to kidney cancer drugs and the care of kidney cancer patients. We have provided exp8rt patient statements at HTA committee meetings of NICE. We attended the NICE committee meetings forthe following appraisals and recommended expert Glinicians and expert patients. beizutilan for VHL RCC patient pathway pilot cabozantiniblnivoltjmab adjuvant pembrolizum8b.
In addition, we attended the SMC committee meetings and PACE meetings and provided written submissions and recommended clinical and patient experts for the following SMC health technology appraisals-. beizutifan for VHL cabozantiniblnivolumab adjuvant pernbrolizumab. We also provided a submission to the National Cancer Medicines Advisory Group INCMAGI for sunitinib and pazop8nib to be used off label. sunitiNib wa3 approved. We are stakeholders and consultees for the NICE Kidney Cancer Guidelines and Rose Woodward 18 a lay member on the NICE Kidney Cancer Guidelines Committee. Flnanclal tevlew Along with many other charities, the economic recession has affected our fundraising activities. People within the patier)t community have been hit especially hard by inflation coming 80 quickly after the problems caused by the pandemic. Once again, we been able c2Pltalise on our excellent reputation for meaningful patient involvement and medicalwriting which, together with grants and donations have provided the income which allows us to provide our wide Tange of patient support services and to look at ways of increasing the support we make avaitable to patients. Ouring the financial year ending 31 st October 2023, ACTION KIDNEY CANCER achieved an income of £134,698 which considering the current financial climate was a good result. Our rnaTragement accountant works closelywith our charity accountants Messrs. Stockdale Account8nts with oversight frorn the Trustees. As part of good governance, the Action Kidney Cancer Trustees have recommend8d an amount of not less than 12 months core costs, be allocated to charity reserves to ensure the future sustainability of the charity is secured. Financial prudence dictates that we place these reserves in a separate bank account. In 2023 w8 were able to access industry grants which have enabled us to achieve the charity aims and objectives. as the charity's reputation grows, we have supported more patients and families than ever before and received an increased number of helpline calls for support. Alongside vital policy work, the charity has maintained its focus on practical patient support, providing patients and families with up-to-date, evidence-based information and we continue to raise awareness and increase Ljnderstanding about kidney cancer at a local. national, and international level whenever the opportunity arises. The Trustees and the management team would like to express their sincere thanks and appreciation to all the volunteers and supporters who have helped us to maintain much needed services to the community in such challenging times. Without the wonderful support from our community and volunteers, wewoLJld not be ableto do what we do. Signed Dated.. 12" july 2024 Mr AndyThomes-Ch8ir ofTrustees, ACTION KIDNEYCANCER
Action Kidney Cancer Statement of Trustees. Responsibilities Th8 truslegs arg responsiblo for preparing the Iruslees, report and the financial statements in accordance with the Unilgd Kingdom A¢counling Standards (United Kingdom Gonerally Accepted Accounting Practice) and applicablo law and regulations. The law applicable to charitie5 requires the Iruslee5 to prepare financial slalemenls loi each financi81 year which give 8 true and fair view of the stale of affairs of the charity and of the incoming r850urces and application of resources of the charity for that period. In preparing these financial slalements, tha Iruslees are required lo.. select suitable accounting policies and then apply them consistently., observe the methods and principles in the Charities SORP., make judgements and estimate5 that are reasonable and prudent., stale whelher applicable accounting standards have been followed, subject lo any material d8partur8s disclosed and explained in th8 financial slatemenls., and prepare the financial statements on the going concem basis unless it is inappropnate to presume that the charity 11 continue in business. The Iruslees are responsible for ke@plng proper accountlng Tgcords that dlsclose wllh reasonabl8 accuracy al any lime the financial position of the charity and enable them lo ensure that the financial statemen15 comply with the Charities Act 2011, the Charities IA¢counts and Reports) Regulations 2008, and the provisions ol the conslilulion. The trustees are also responsible for safeguarding the assets of the charlly and hence for taking reasonable steps for the prevention and detection of fraud and other irwularities. The Irusleas are responslble for the maSnl8nance and Snl8grily of the corporal8 and financial Information included on the charllable company's website. Legislaliors governin9 the preparation and dissemination of financlal stalemenl$ may differ from legislation in other juri5dicllons. Approved by the tnjslees of the charity on and sSgned on Ils behalf by.. A Thomas Chairman and trustee Page 8
Action Kidney Cancer Independent Examinerfs Report to the trustees of Action Kidney Cancer I report lo the trustees on rny examination of the accounts of Action Kidney Cancer for the year 8ndod 31 October 2023. Responslbllltl6s and basis of report As the charity trustees of Action Kidney Cancer you are responsible for the preparalion of the accounts in accordance with the requirements of the Charities Act 2011 I'lhe Acl'}. I report in respect of my examin81ion of the Action Kidney Cancer's accounts carried out unéer section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145{51{bl of the Act. Independent examiner's Statèment I have completed my examination. I confirm that no malerial matters have come to my attention in connection with the examination giving me cause lo believe that in any material respect.. accounting records were not kept in respect of Action Kidney Canr as required by section 130 of the Act,. or 2. the accounts do not accord with those records.. or 3. the accounts do not comply with the accounting requirements concerning the loTh and content of accounts sel out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view, which is not a matter considered as part of an independent examination. I have no concems and have come across no other matter5 in connection w5th the examination to which attention Should be drawn in this report in order lo enable a proper understanding of the accounts to be reached. HaOey H811 FMAAT St Ingunger Offices Lanivet Bodmin Cornwall PL30 5HS Page 9
Actlon Kidney Cancer Statement of Financial Activities for the Year Ended 31 October 2023 Unrestricted funds Total 2023 Note Income and Endowments from: Donations and legaaes Other income 104,633 30. 104,633 30,064 Total income 134,697 134,697 Expenditure on.. Charitable adivities 100,582 100,582 Total expenditure 1100.582 100,582 Net income 34,115 34,115 Net movement in funds 34,115 34,115 Rèconciliation of funds Total funds brought forward 254,709 254,709 Total funds carried forward 11 288.824 Unr85trict8d funds 288,824 Total 2022 Note Income and Endowments from: Donations and legacies Otr income 106,704 30,371 106,704 30.371 Total incow 137,075 137,075 Expendlture on: Chanlable actmties 187,212 87,212 Total expenditu 87.212 87,212 Nel income 49,863 49.863 Nel movemenl in funds 49,863 49,863 Re¢onciliation of funds Total funds brought forward 204,846 204,846 Total funds carried forward 11 254,709 254,709 All of the charity's activities derive fM ntinry operations during the above periods. The funds breakdown for 2022 is sFK)wn in note 11. The notes on pages 12 10 19 fomi an integral part of these finanoal statements. Page 10
Action Kidney Cancer (Registration number: 1164238) Balance Sheet as at 31 October 2023 2023 2022 Note Fixed assets Tangible assets 243 CurTent assets Debtors Cash al bank and in hand 20.645 275,489 19,503 238,69S 296,134 258,198 ¢ditors. Amounts falling due within one year Net current assets 10 7,310 {3,732} 288,824 254,466 Net assets 288.824 254.709 Funds of the ¢harity: Unrestricted income funds Unrestricted funds 288,824 254,709 Total tunds 11 288,824 254,709 Thefi on an 81 statements on pages 10 to 19 were approved by the trustees. and authorised for issue and signed on their iEhaff by. A Thomas Chairman and truslee The notes on pages 12 10 19 form an integral part of these financial statements. Page11
Action Kidney Cancer Notes to the Financial Ststements for the Year Ended 31 October 2023 1 Ac¢ounling policles Statement of cofflplianc• The financial statements have been prepared in accordance with the second e(lition of the Charits8s Slalement of Recommended Practice issued in October 2019. the Financial Reporting Standard applicable In the United Kingdom and Republi¢ of Ireland IFRS 1021 and the Charities Act 2011. Bas1• of preparation Action Kidney Cancer meets the defintlion of a public benefit enlty uTrY8r FRS 102. The accounts (financial stalementsl have been prepared under the historical cost conv&ntson with Items recognised al cost or transaction value unless olhernyise ststed in the relevant nolelsl to these accounts. Golng conc•m The trustees consider that there are m malenal uncertainties about the charills ability lo continue as a going eoneom. Income and endowments Voluntary income Including dations. gifts, Waos and grants that prowde core funding or are of a gengral nature is recognised when thè Charity has entillernenl lo the income, tt is probabla that the income wll be received and the afflnt can be measured $uffi¢ient reliability. Donatlons and l•gacles Donations and legacies are recogned on a receivable basis when receipt is probable and the amount can be reliably measured. Grants recelvable Gfanls are recognised when the charity has an entiilement lo the fvnds and any eanditions linked to the grants have been mel. Where performance condrtics are attached to the grant and are yel lo ba mel, the income is recognised as a liability and induded on the balanLx sheet as deferred income lo be released. Exp•ndlturo AJI expenditure is recognised once there Is a legal or constructive oblpats'on lo that expenditure, il is probable settlement is required an(1 the amounl can be measured relkqbly. AJI costs are allocated lo the applicable expen¢Jiture heading that aggregate wmilar costs to thal category. Where costs cannot be directly attributed to particular headings they have been allocated on a basls consislenl with Ihfr use of resources. wth central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support Costs are allocated based on the spread of stsff Gosts. Charltable activlties Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its benefioarie5. It indudes both costs that can be allocated directly to such activities and those costs of an indireth nature n&$S8ry to support them. Page 12
Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 {continued) Taxation The charity is Conside4 to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tsx purposes. Accordingly, the tharity is tentiallY exempt from tsxation in respect of income or capital gains received wlhin categories cOVed by Chapter 3 Part 11 of the Corporation Tax ACL 2010 or Section 256 of the Taxation of Chargeae Gains Act 1992. to the exlenl that such income or gains are applied exdusively lo charitae purposes. Tangible fixed assets Individual fixed assets costing £100.(Kl or more a inilially recorded at cost. D8pre¢iation and amortisation Depreciation Is provided on tangible fixed assets so as lo wrrte off the cost or valuation, less any estimated residual value. over their expected useful eConCniC life as fdlows" Trade debtors Trade debtors are amounts due from eu5tomer5 for merthandr)e sokl or services performed in the ordinary course of busine5S. Trade debtors a recognised initially at the transaction wice. They are subsequendy measured al 8mortised cost using the effective inleresl method, less proVisn for impaimienl. A provision for the impairment of trade debtors is established when the is objective evidence that the charity will not be able lo collect all amounts due according to the original lemis of r1VableS. Cash and cash equivalenls Cash and Cash equivalents cornpiise cash on harKI and call detM)sils, and other short-lerm hyhly liquid investments that are readily converbble to a known amount of cash and are subject to an insignificant risk of thange in value. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable a classtfied as current liabilities if the does not have an unconditional right, al the end of Ihe reporting peri1. lo defer settlement of the creditor for at least velve months after the porting date. If there is an un¢(Thlitional right lo defer sewemenl for al least hvelve months after the PortIng date. they a pyesented as rnn-current liabilities. are recognised initially at the transaclKfyn price and subsequenuy measured at amortised cosl using the effectNe interest melhixl. Page 13
Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 (continued) Borrowings Intefesl-bearing borrowings are initially cOrde¢l at fair value, nel of transaction costs. Inleresl-bearing borrowings are subsequentty carried at amortised cost, with the diffeTrnce L)eeen the proceeds, net of transaction costs, and the amount due on fedemption being recognised as charge lo the Stslernent of Finanoial Activities over the peric*fj of the levant boffowing. Interest expense is recognised on the basis of the effective interest method and is included in in18resl payable and similar charges. Borrowings are dassified as current liabilities unless the tharity has an Ur)ndItiOnal right to defer settlemenl of the lialty for at least tWee months after the reporling date. Fund structure Unreslricled income funds are general fvnds thal are availatAe for use at the trustees discretion in furtherance of the objectives of the charity. Financial instrumenls Classification Financial assets and financial liabilities are rew9lled vknen charrty becomes a party to the ontractual provisions of the inslrum8nl. Financial liabililies and equity inslrumenls are dassffied according lo the substance of the contractU81 arrangements entered inlo. An equity instrument is any )ntract that eviderKes a residual interest in Ihe assets of the charity after deducting all of its liatmlilies. Recognition and measurement All financial assets and liabilities are inilialty measured al transaction price (including transaction costsl, except for tIN)se financial assets classified as al fair value through profit or loss, which are initsal measured at fair value (which is nomially the transaCtn price exduding transaction coslsl. unless the arrangement conslttutes a financing Iransaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability 15 measured at the present value of the future payments d¢scounled at a market rate of interest for a similar debt instrument. Financial assets and liabilities are only offset in the statement of finanoal p0SOn when, and only when there exists 8 legally enforceable right to set off the recognised amounts and the charity intends either lo setJe on a nel basi5, 01 to reali5e Ihe asset and settle the Ikibilty simultsneously. Financial assets are derecognised when and only when al the contractual rights lo the cash flows from the financial asset exre or are settled, bl the charity tran5feTS lo another party substsntially all of the risks and rewards of ownership of the financi asset, or cl the charity, despite having retained some. but not all, significant risks and rewards of ownership, has transfeThed control of the asset lo anoth&r paty. Financi31 li8bilikn.es a derecognised onty when Ol1g8110n SFecifEd in the contract is discharged. cancelled or expires. Page 14
Action Kidney Cancer Notes to the Financial Stalements for the Year Ended 31 October 2023 (continued) Debt instrymOlJts Debt instmments which meet the following condrtions are subsequentty measured al amortised cost using the effective interest method.. (al The conlraclual retum to the holder is (i} a fixed amount," lil) a positive re rate or a positive variable rate,. or {iiil a combination of a posrb.ve or a negative fixed rate and a positive variable rate. (bl The contract may provide for repayments of the principal or the rern to the holder (but not both) lo be linked lo a single relevant observable index of general pri inflalion of the currency in which the debt instrument is denominated, provided such links are not leveraged. Icl The contract may provide for a delemiinable varialn of the relum to the holder during the life of the inslrumenl, provided that li} the new rate sab"sfies condition la} and the variation is not contingent on future events other than 111 a change of a contractual variabte rate", {21 lo protect the holder against credit deterioration of the issuer.. {31 change5 in levie5 applied by a central bank or arising from changes In relevant taxation or law- or lill the new rale is a rnarket rate of interest and satisfies condition lal. (d) There is contractual provision thal c(MJld. by its temis. resutt in the holder losing the principal amount or any interest attributable lo the current period cff prior periods. el Contractual provisions Ihat permit the ISSU lo prepay a debt instNmenl or permit the h¢Jder to pul il back lo the issuer before maturity are not contingent on future events, other than to protect th8 holder again51 the credit deterioration of the issuer or a change in control of the issuer, or lo protect the holder or Issuer against changes in levies applied by a central bank or arising from changes in relevant taxaln or taw. lfj Contractual provisKJns may pemit the extension of the term of the debt instrument. provided that the return to the holder and any other contradual provisions applicable during the exlended temi S31isfy the conditions of paragraphs lal lo {c). Debt instruments that are dasstfied as payable or receivable wthin one year on initial cOgni1k)n and which meet the above conditi.ons are Ineasured at the undiscounted amount of the cash or other consideration expected lo be paid or received, nel of impaimenL With the exception of some hedgiThJ instruments. other debt instruments not meeting these conditions are measured at fair value through profft or loss. Commitsnenls to make and receive loans whw* meet the o)ndibons mentiongJ above are measured al cost (which may be nil) less impaim)enL Investments Investments non-1xVertIble preference shares and nonrf)uttable ordinary or preference shares {where shares are publidy traded or their fair value is reliably measurable) aTe measured at fair value through profil or loss. Where fair value cannot be measured rlay, investments are measured at cost less impaimient. Investments In subsidiaries and associates a measured at cost less impaimienl. For investments in subsidiaries acquired for consider8ts.on Induding the issue of shares qUalIng for merger relief. Gost is measured by referen to Ihe wminal value of the shares issued plus fair value of other consmleration. Any premiurn is ignored. Page 15
Aclion Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 (continued) Derivative financlal instruments The charty uses derivative financial instruments to reduce exposure to foreign exchange risk and interest rate movements. The charity not hold or Issue derivative finanaal instruments for speculative purposes. Derivatives are initially recognised at fair value at the date a derivatNe contract is entered into and 8re subsequently MeaSUr to their fair value at each repong date. The resulting gain or loss is recognised in statement of financial actrvities immediately unless the derivative is éesignaled and effective as a hedging instrument, in which event the kn.ming of the recognition in statement of financial activities depends on the nature of the trge relatsonship. Falr value measurement The best evidence of fair value is a quoted for an identical asset in an active rnarkel. When quoted prices are unavailaNe, the wice of a recent transaction for an Njentical asset provides evidertce of fair value as long as there has not been a significant change in economic circtjmstances or a significant lapse of lime since the tr8nsacb.on tix)k pla(E. If the market not active and recent transactions of an identical asset on their own are not a good estimate of fair value. the fair value is ests'maled by using a valuation technu. 2 Income from donation$ and legacios Unrestrlcted funds General Total funds Donations and legaaes., Donations from individuals Grants, including capital grants: Grants from other charities 29.633 29,633 75,000 75,000 Total for 2023 104.633 104.633 Total for 2022 1Ckf.704 106,704 3 Oth8r income Unrestricted lunds General Total funds Advocacy Fees Totsl for 2023 30.064 3D,064 30,064 Totsl for 2022 30.371 3D,371 Page 16
Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 (continued) 4 Expondlture on charitable activities UTrre$tricted fvnds General Total funds Note support of kidney cancer patients Depreciation, amortisation and other similar costs 100.339 243 100,339 243 Total for 2023 100,582 1 OD,582 Total for 2022 87,212 87,212 5 Trustges remuneration and exp•nsg5 No trustees. nor any persons connected with them. have receive(l any remuneration the charty during the year. No trustees have received any reimbursed expense5 or any other benefits from the charity during the year. 6 Taxation The charty is a regislered charity and therefore exempt from taxalM)n. 7 Tangible fixed assets Fumlture and oquipm8nt Total Cost At 1 November 2022 1.216 1,216 At 31 October 2023 1.216 1.216 Deprociation At 1 November 2022 Charge for the year At 31 October 2023 973 243 973 243 1,216 1,216 Net book value Al 31 October 2023 Al 31 October 2022 243 243 Page 17
Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 (continued) 8 Debtors 2023 2022 Trade debtors Prepayments 400 20,245 19.338 165 20.645 19,503 9 Cash and cash oquivalents 2023 2D22 Cash at bank 275.489 238,695 10 Cr9ditors: amounts fall•ng duo within ono y•ar 2023 2022 Trade creditors Accruals 7.210 100 3,330 402 7,310 3,732 11 Funds Balancè at 1 November 2022 Incoming resources Resources expended Balanc& at 31 October 2023 Unrestricted General 254,709 134,697 100,582 288,824 8alan¢g at 1 Novgmbgr Incomlng resources R•source8 expended Balance at 31 Octobgr 2022 2021 Unrestricted General 137.075 187.2121 254,709 Page 18
Action Kidney Cancer Notes to the Financial Statements for the Year Ended 31 October 2023 (continued) 12 Analysis of n¢t assets between funds Unr8strithd Total funds 2023 Genèral Current assets Current liabiltbes 296,134 17,310 296.134 7,310 Total nel assets 288.824 288,824 Unrestricted Total funds 2022 General Tangible fixed assets Current assets Current liabilities 243 258.198 3.732 243 258,198 3,732 Total nel assets 254,709 254.709 Page 19
Action Kidney Cancer Detailed Statement of Financial Activities for the Year Ended 31 October 2023 Total 2023 Total 2022 Incom8 and End0Yents from: Donations and legacies {analysed bek)w) Other Income lanaly5ed lOw) Total Income 104,633 30.064 106,704 30,371 134,697 137,075 Expenditure on.. Charitable ath'vib'es lanalysed kxlowl Totsl expenditure 1100,5821 187.212 100,582 187,2121 Net income 34,115 49,863 Nel movement in funds 34,115 49,863 Reconciliation of funds Total funds brought forward Total funds canied forward 254.709 204,846 288,824 254,709 This page does not form part of the statutory finanaal statements. Page 20
Action Kidney Cancer Detailed Statement of Financial Activities for the Year Ended 31 October 2023 (continued) Total 2023 Total 2022 Donations and legacies Appeals and donations Grants - other agencies 29,633 75.000 26,704 80,000 104,633 106,704 Other Income Advocacy fees 30.371 30,371 Ch•rlt•ble •ctlvldes Rent Insurance Advocacy and medical relatsons Telephone and fax Communieation$ Office and adminislralion Websrte and maint8nance Patient Support Sundry expenses Conferences Project management Travel and subsistsnce Marketing Material Fundraising costs Charity ffleeling Accountancy fees Legal and professh)nal fees l Giving plattorm charges Deprecialion of office equipment (6601 12 28,3141 11681 111,1851 (8.6571 17,7441 14.7501 {240) 1495) 1301) 125.439) 1201) 110.380) 6.441) 17.9141 116,2601 141 11251 16.0001 11611 16521 110,8801 (7,838) 11,087) (23) (11,970) (5.071) 1100) {1,1801 11,3641 243 11001 11,0251 15911 243 100,S82 87,212 This page does not fomi part of the statutory finanryal statements. Page 21